Regeneron Pharmaceuticals (NASDAQ:REGN) Earns “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued to investors on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has a $1,282.00 price objective on the biopharmaceutical company’s stock.

REGN has been the subject of a number of other reports. JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an overweight rating in a research note on Friday, August 2nd. TD Cowen lifted their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a buy rating in a report on Tuesday, July 23rd. StockNews.com raised Regeneron Pharmaceuticals from a buy rating to a strong-buy rating in a report on Tuesday, September 10th. Canaccord Genuity Group reaffirmed a buy rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Finally, Barclays lifted their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an overweight rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of Moderate Buy and a consensus target price of $1,111.30.

Regeneron Pharmaceuticals Trading Up 1.0 %

Regeneron Pharmaceuticals stock opened at $1,150.19 on Tuesday. Regeneron Pharmaceuticals has a one year low of $769.19 and a one year high of $1,211.20. The business’s fifty day moving average is $1,130.85 and its 200 day moving average is $1,030.53. The stock has a market capitalization of $126.73 billion, a PE ratio of 33.98, a price-to-earnings-growth ratio of 3.97 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter last year, the firm posted $8.79 EPS. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals will post 37.8 EPS for the current year.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at $1,467,684. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The disclosure for this sale can be found here. Insiders have sold 10,026 shares of company stock worth $11,498,705 over the last ninety days. Corporate insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Brown Lisle Cummings Inc. lifted its position in shares of Regeneron Pharmaceuticals by 18.2% in the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 10 shares in the last quarter. Sachetta LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares in the last quarter. Team Hewins LLC lifted its position in shares of Regeneron Pharmaceuticals by 2.5% in the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 11 shares in the last quarter. Angeles Wealth Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 3.5% in the first quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 11 shares in the last quarter. Finally, TrinityPoint Wealth LLC lifted its position in shares of Regeneron Pharmaceuticals by 4.8% in the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 12 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.